Effect of rosiglitazone on circulating malondialdehyde (MDA) level in diabetes based on a systematic review and meta-analysis of eight clinical trials

Patients with type 2 diabetes have high levels of malondialdehyde (MDA), and clinical data suggest a reducing effect of rosiglitazone (RSG) on the level of MDA in these patients. However, the results of available studies on the level of MDA in RSG-treated patients are not univocal. This meta-analysi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of Investigative Medicine 2021-03, Vol.69 (3), p.697-703
Hauptverfasser:	Majidi, Ziba, Hosseinkhani, Shaghayegh, Amiri-Dashatan, Nasrin, Emamgholipour, Solaleh, Tutunchi, Sara, Hashemi, Javad, Ghorbani, Fatemeh, Koushki, Mehdi
Format:	Artikel
Sprache:	eng
Schlagworte:	Bias Clinical trials Clinical Trials as Topic Diabetes Diabetes Mellitus, Type 2 - drug therapy Drug dosages Enzymes Humans Insulin resistance Kinases Lipid peroxidation Lipids Malondialdehyde - blood Meta-analysis Metabolism Oxidative stress Rosiglitazone - therapeutic use Software Systematic review
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!